Contineum Therapeutics (CTNM) Non-Current Assets (2023 - 2026)
Contineum Therapeutics (CTNM) posted quarterly Non-Current Assets of $7.8 million for Q2 2026, up 28.73% year-over-year from $6.0 million in Q2 2025, and down 7.13% quarter-over-quarter from $8.4 million in Q1 2026.
Contineum Therapeutics (CTNM) Non-Current Assets (2023 - 2026) Analysis & Trends
Contineum Therapeutics' Non-Current Assets history runs 4 years deep, the most recent figure standing at $7.8 million for Q2 2026.
- In Q2 2026, Non-Current Assets rose 28.73% year-over-year to $7.8 million; the TTM figure through Jun 2026 stood at $30.8 million (up 57.8% YoY), while the FY2025 annual figure was $8.7 million, up 35.08% from the prior year.
- Non-Current Assets for Q2 2026 stood at $7.8 million, down from $8.4 million in the prior quarter.
- The five-year high for Non-Current Assets was $8.7 million in Q4 2025, with the low at $891000.0 in Q3 2024.
- The 4-year median for Non-Current Assets is $6.0 million (2025), against an average of $5.3 million.
- The sharpest annual moves came in 2025 and 2026: Non-Current Assets jumped 564.42% in 2025, then advanced 28.73% in 2026.
- Contineum Therapeutics' Non-Current Assets stood at $2.7 million in 2023, then soared by 141.01% to $6.5 million in 2024, then jumped by 35.08% to $8.7 million in 2025, then slipped by 10.75% to $7.8 million in 2026.
- Business Quant data shows CTNM's Non-Current Assets at $7.8 million in Q2 2026, $8.4 million in Q1 2026, and $8.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Contineum Therapeutics | 533.73 Mn | 533.73 Mn | - | 7.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.79 Mn |
| Mar 31, 2026 | 8.39 Mn |
| Dec 31, 2025 | 8.73 Mn |
| Sep 30, 2025 | 5.92 Mn |
| Jun 30, 2025 | 6.05 Mn |
| Mar 31, 2025 | 6.13 Mn |
| Dec 31, 2024 | 6.46 Mn |
| Sep 30, 2024 | 891,000.00 |
| Jun 30, 2024 | 1.04 Mn |
| Mar 31, 2024 | 3.85 Mn |
| Dec 31, 2023 | 2.68 Mn |